Drug Utilization Review Board
Minutes Draft

Name of Meeting:	Drug Utilization Review Board
Date of Meeting:	September 14, 2023
Length of Meeting:	2 hours and 57 minutes
Location of Meeting:	DMAS Board Room 102

Members Present:
Rachel Cain, PharmD, Chair
Denese Gomes, NP
Kristi Fowler, RPh
Matthew Estes, PharmD
Melissa Chouinard, MD
Michele Thomas, PharmD
Seth Brant, MD

Members Not Present:
John Morgan, MD, Chief Clinical Innovation Officer
Denise Lowe, PharmD
Elizabeth Gaughan, MD
Kathryn Reid, PhD
Wendy Nash, PharmD

DMAS Attendees:
Lisa Price Stevens, MD, MPH, MBA, FACP, CHIE, Chief Medical Officer
MaryAnn McNeil, RPh, Pharmacy Manager
Kiara Jasper, MHA, CPhT, Pharmacy Systems Administrator

Contractors:
Debbie Moody, RPh, Director, Clinical Account Services, Magellan Rx Management
Nancy Eldin, PharmD, Pharmacist Account Executive, Magellan Rx Management
Jeni Hodzic, CPhT, Senior Account Management Specialist, Magellan Rx Management

Visitors:
Alex Tabraue
Brian Trentler
Jane Oshinsky
Jeannie Perry
Joe Kupiec
John Minneci
Laurie Mauthe
Mark Vaughan
Reema Sbitany
Rob Berringer
Steve Kahn
Steve Patterson

Call to Order and Introductions

Dr. Rachel Cain welcomed and thanked everyone for attending the DUR meeting. Dr. John Morgan was unable to attend and designated Dr. Cain to chair the meeting.

Dr. Cain called the meeting to order at 1:03 pm.

Minutes – June 8, 2023

Kristi Fowler motioned to approve the June 8, 2023 meeting minutes as submitted. Dr. Melissa Chouinard seconded the motion.

By-Laws Review

Dr. Cain discussed the updates to the DUR By-Laws. Changes were reviewed and will be voted on at the next DUR meeting on December 14, 2023.

New Drugs

The DUR Board reviewed Cuvrior™ (trientine tetrahydrochloride), Daybue™ (trofinetide), Furoscix® (furosemide injection), Skyclarys™ (omaveloxolone) and Veozah™ (fezolinetant). The Impact Reports and the report for the utilization of these 5 new DUR drugs for Fee-For-Service (FFS) and Managed Care Organizations (MCOs) were reviewed.

The DUR Board discussed the service authorization (SA) criteria for Cuvrior™. The DUR Board wanted clarification on question number 5 “why should the member be switched if the member is stable and tolerating penicillamine?”. The board recommended tabling the discussion about the Cuvrior™ SA form. Board members agreed to adding an additional question to assess tolerability of penicillamine on the SA form and this will be presented at the next DUR meeting. After discussion by the board, Dr. Michele Thomas motioned to table the SA criteria for Cuvrior™ until the next DUR meeting on December 14, 2023. Denese Gomes seconded the motion.

The DUR Board reviewed the SA criteria for Daybue™. After discussion by the DUR Board, Ms. Gomes motioned to accept the SA criteria with the following new updates: to remove question numbers 5 and 8 and add a new question to be number 1 stating “Is Daybue prescribed by or in consultation with a neurologist?”. Dr. Matthew Estes seconded the motion.

The DUR Board reviewed the SA criteria for Furoscix®. After discussion by the DUR Board, Ms. Fowler motioned to accept the SA criteria with the following new updates: remove “AND” from the end of question numbers 1 and 2; remove “AND” from the end of question numbers 5 and 6, combine the questions to state “Does the member have anuria or hepatic cirrhosis or ascites or acute pulmonary edema?” and move the new question up to be question number 3; change the approval length to 90-day approval; add a quantity limit of 3 units per 90 days, and remove the renewal portion of the SA form. Dr. Thomas seconded the motion.

The DUR Board reviewed the SA criteria for Skyclarys™. After discussion by the DUR Board, Dr. Thomas motioned to accept the SA criteria with the following new updates: remove the word “AND” after the end of each question and remove question number 11. Dr. Estes seconded the motion.

The DUR Board reviewed the SA criteria for Veozah™. After discussion by the DUR Board, Dr. Estes motioned to accept the SA criteria with the following new updates: remove the word “AND” after the end of each question and move question number 8 up to be question number 3. Ms. Gomes seconded the motion.

MRx Pipeline and DUR Quarterly Newsletter- The July 2023 MRx Pipeline Report and the June 2023 DUR Quarterly Newsletter were both available on the DUR Webportal for review.

Topics for Discussion

Antipsychotic Medications in Children – The DUR Board reviewed Antipsychotic Medications in Children reports for FFS and MCOs and requested a follow-up for children 2 years of age and younger being prescribed an antipsychotic.

Antidepressant Medications in Children – The DUR Board reviewed Antidepressant Medications in Children reports for FFS and MCOs and requested a follow-up for children 2 years of age and younger being prescribed an antidepressant.

Mood Stabilizer Medications in Children – The DUR Board reviewed Mood Stabilizer Medications in Children reports for FFS and MCOs and requested a follow-up for children less than 2 years of age being prescribed a mood stabilizer.

Overlaps in Antipsychotics, Antidepressants and Mood Stabilizers in Children – The DUR Board reviewed Overlaps in Antipsychotics, Antidepressants and Mood Stabilizers in Children reports for FFS and MCOs.

Synagis® – The DUR Board reviewed the Synagis reports and SA form. After discussion by the DUR Board, Dr. Thomas motioned to accept the SA criteria with the following new update: add an informational non-decision-making question asking if the member or member's mother have a history of taking the RSV vaccine. Ms. Fowler seconded the motion.

Reports

ProDUR

The DUR Board reviewed and discussed the ProDUR reports. The DUR Board is interested in having a similar report to "ProDUR Top Encounters by Problem Type – Severity 1" but this report will be for the lower severity levels.

RetroDUR

I. Recent RetroDUR Activity

The DUR Board reviewed the Recent RetroDUR Activity reports.

II. RetroDUR Criteria Estimates

The DUR Board reviewed the Criteria Exception Estimates Reports. The reports were broken down to the Top 40 Criteria Exception Estimates by Members and the Top 40 Criteria Exception Estimates by Total Payment Amount for FFS and each individual MCO plan.

- Members were interested in the following criteria for lettering:
  - Criterion number 7735: Atypical antipsychotics without metabolic testing
  - Criterion number 8083: GIP or GLP-1 claims without a diagnosis of diabetes or prediabetes in history
  - Criterion number 22454: Use of atypical antipsychotics in children < 18 without metabolic testing

Utilization Analysis

The DUR Board reviewed the Utilization Analysis reports. The DUR Board would like to know if the generic name on the "Top 25 All Drugs Ranked by Claim Count" and "Top 25 All Drugs Ranked by Payment Amount" reports distinguish for a specific brand name version of the drug or does the generic name include all the different brands with that generic name. This information will be researched.

Dr. Lisa Price Stevens requested a utilization and uptake analysis for Furoscix® after the SA goes into effect for about 6 months or greater and looking at hospitalizations.

Next DUR Meeting

December 14, 2023

Dr. Chouinard motioned to adjourn the meeting. Dr. Thomas seconded the motion.

Meeting adjourned at 4:00 pm.